Smooth muscle cell proliferation in the intima of arteries is a principal event associated with vascular narrowing after balloon angioplasty and bypass surgery. Techniques for limiting smooth muscle cell proliferation, however, have not as yet yielded any therapeutic benefit for these conditions. This may reflect the present lack of sufficiently potent and specific inhibitors of smooth muscle cell proliferation. DAB389 EGF is a genetically engineered fusion protein in which the receptor-binding domain of diphtheria toxin has been replaced by human epidermal growth factor. We evaluated the effect of this fusion toxin on human vascular smooth muscle cells in culture. Incubation of proliferating cells with DAB389 EGF yielded a dose-dependent inhibition of protein synthesis, as assessed by uptake of [3H]leucine, with an IC50 of 40 pM. The cytotoxic effect was inhibited in the presence of excess EGF or with monoclonal antibody to the EGF receptor. We further studied the effect of the fusion toxin on smooth muscle cell outgrowth from human atherosclerotic plaque. Outgrowth was markedly inhibited after as little as 1 h of exposure to the fusion protein.
Introduction
Approximately 40% of atherosclerotic arteries treated by balloon angioplasty develop a recurrent lesion at the site of the angioplasty procedure in the six months following this intervention ( 1, 2). In animals, a principal response to vascular injury is the rapid accumulation of smooth muscle cells in the intima of the vessel wall (3) (4) (5) . In human lesions that develop after angioplasty (restenosis lesions), an abundance of smooth muscle cells is a consistent histologic feature (6) (7) (8) (9) . Rapid accumulation of intimal smooth muscle cells is therefore considered to be an important process contributing to the occurrence of restenosis after angioplasty, and to the formation of other rapidly developing lesions, such as those that develop after coronary and peripheral artery bypass surgery, cardiac transplantation, and carotid and coronary endarterectomy ( 10) . These forms ofatherosclerosis have, to date, been refractory to a variety of mechanical and pharmacological therapies. This may reflect, in part, the present lack of sufficiently potent~and specific inhibitors of smooth muscle cell accumulation. Furthermore, although certain agents demonstrate efficacy in animal models, there are no reports demonstrating efficacy specifically with human vascular smooth muscle cells, including those within or derived from atherosclerotic lesions.
EGF is a mitogen for vascular smooth muscle cells. Recently, smooth muscle cells proliferating in culture were found to express a higher number of binding sites for EGF than nonproliferating smooth muscle cells in culture ( 11 ). A differential expression of EGF receptors may provide the opportunity for using cytotoxic agents that specifically target proliferating smooth muscle cells, and thereby inhibit their repopulation of the arterial intima. Targeted delivery of cytotoxins to specific cell surface receptors may be accomplished with recombinant fusion proteins. One such molecule, DAB389EGF, has recently been engineered and has been shown to be cytotoxic to EGF receptor-bearing tumor cells ( 12) . The hybrid gene for this protein consists ofthe diphtheria toxin gene with the sequences encoding the receptor binding domain replaced by those coding for human EGF. The mechanism of toxicity is similar to that of native diphtheria toxin (12) (13) (14) (15) . After receptor binding and internalization of the protein, the enzymatically active fragment A of diphtheria toxin catalyzes the nicotinamide adenine dinucleotide-dependent ADP-ribosylation of elongation factor 2. This reaction arrests protein synthesis, causing cell death.
We have investigated the effect of this recombinant toxin on proliferating human vascular smooth muscle cells. We found that DAB389EGF is highly cytotoxic to human smooth muscle cells and we demonstrated that this effect is mediated by the EGF receptor. Furthermore, the fusion protein can inhibit smooth muscle cell outgrowth from explanted human atheroma, and can prevent smooth muscle cell proliferation within these growth-stimulated lesions.
Methods
Bacteria strains. Escherichia coli strain DH5aF' (Bethesda Research Laboratories, Gaithersburg, MD) was used for M13 cloning. Strain SCSI (Stratagene Inc., La Jolla, CA) was used as the host for the production of DAB389EGF.
Construction ofvectors. Construction ofthe plasmid used to express DAB389EGF has been described previously ( 12) . Briefly, this entailed modifying a parental plasmid, pSI 123, which encodes the fusion protein DAB486IL-2, consisting of the first 485 amino acids of diphtheria toxin fused to a synthetic IL-2 gene ( 16) . A synthetic gene for EGF was annealed and ligated to Ml3mpl8. A clone designated M13EGF#2 was confirmed to have the correct sequence and was used to replace the IL-2 coding region from pSI123 with the EGF coding region. This yielded the plasmid pSE I which has been used to express DAB,"6EGF ( 12 ) . The gene encoding DAB389EGF was constructed by digestion of the plasmid pSE1 with Clal and SphI and ligation with the ClaI/SphI fragment of pDW27 (17) . The resulting plasmid, pSE5, contains a 97 amino acid deletion of the diphtheria toxin. The expressed fusion protein, DAB389EGF, has been shown to be 10-100-fold more cytotoxic to EGF receptor-expressing tumor cell lines than DABa6EGF (12) .
Expression and purification of DAB389EGF. To express DAB389EGF, E. coli strains were transformed with plasmid pSE5, then grown for 13-17 h at 30'C, and induced with isopropyl-ft-D-thiogalactopyranoside. Cells were collected and lysed and the fusion protein was purified as previously reported ( 12) . This entailed a three-stage protocol that included immunoaffinity, anion exchange, and gel filtration chromatographies. Endotoxin levels ofthe final preparation were < 30 endotoxin units per mg of protein.
Cell culture. Vascular smooth muscle cells were cultivated by explant outgrowth from unused portions of internal mammary arteries retrieved at the time of open heart surgery. Cell cultures were grown in medium 199 (M199; Gibco Laboratories, Grand Island, NY) supplemented with 10% fetal bovine serum, unless otherwise indicated. Experiments were performed using cells in the second or third subculture. Smooth muscle cell identity was confirmed by positive immunostaining with monoclonal antibody to smooth muscle a actin (clone 1A4; Sigma Chemical Co., St. Louis, MO) and lack ofstainingwith monoclonal antibody to Factor VIII-related antigen (Signet Laboratories, Dedham, MA).
Smooth muscle cellprotein synthesis. Cells were seeded on to fibronectin-coated wells (10 jg/cm2) at a density of 5,000 cells/cm2 and Smooth muscle cell outgrowth assay. Smoot growth from explants of human atherosclerotic p1 as previously described ( 18) . Briefly, atherosclerol trieved from patients percutaneously by directiona vices for Vascular Intervention, Redwood City, C face was gently scraped to dislodge endothelial cells divided into 75-90 fragments, each measuring allowed to adhere to the surface of fibronectin-c( (five fragments per 9.4 cm2 well) in media (M 199; C supplemented with 15% fetal bovine serum. Unde cells migrate from the lesion and proliferate, yieldi smooth muscle cells, the identity of which were coi immunostaining for smooth muscle a actin (clone ] cal Co.). 24 h after placing the explant frag DAB389EGF was added to the media at concentra 10-14 M to 10-7 M. The proportion of explant fral outgrowth ofat least one smooth muscle cell was del d. In these experiments the media was not exchange vation period (14-15 d (Fig. 1  a) . The concentration at which protein synthesis was inhibited by 50% (IC50) was 40 pM (1.9 ng/ml). Three separate experi-*4---@ * Control ments demonstrated that the cytotoxic effect of DAB389EGF was mediated through the EGF receptor. First, incubation of cells in the presence of 1.6 AM human recombinant EGF resulted in a dose-dependent inhibition of cytotoxicity, as measured by incorporation of radiolabeled leucine (Fig. 1 b) . Second, incubation of cells in the presence of 10-8 M monoclonal antibody to the human EGF receptor (Upstate Biotechnology, Inc.) led to a similar inhibition of cytotoxicity (Fig. 1 c) . and, unlike the EGF fusion toxin, this protein was not cytotoxic, up to a dose of 10-8 M (Fig. 1 d) . At very high concentrations (I 0-7 M) of DAB389IL-2 a cytotoxic effect was evident.
12 16 This is consistent, however, with previous findings (19) in which a toxic effect of DAB389IL-2 on IL-2 receptor-deficient cells was seen at this high dose. We subsequently evaluated the effect of DAB389EGF on the in vitro outgrowth of smooth muscle cells from intact segments h muscle cell outof human atheromata. The outgrowth of cells from atheroscleaque was evaluated rotic plaque explanted into a growth-stimulating culture envitic plaques were reronment represents the integrated consequences ofboth migrad atherectomy (De- tion and proliferation of smooth muscle cells ( 18) . It can thus 4). The lumen surbe considered to be a similar response to that which occurs in . Lesions were then vivo, following trauma to the atherosclerotic vessel wall. Fig. 2 EGF ( 10-6 M), the ability to yield an outgrowth of smooth muscle cells was retained, although the outgrowth from individual explants was less than that of untreated controls. When explants were incubated with 10-9 M DAB389EGF and 10-6 M EGF both the proportion ofoutgrowing explants and the number of smooth muscle cells that accumulated around the individual explants was similar to that of controls. The length oftime that human atherosclerotic plaque must be exposed to DAB389EGF to induce inhibition ofsmooth muscle cell outgrowth is depicted in Fig. 2 c. The proportion of explants yielding an outgrowth of smooth muscle cells was markedly reduced after as little as 1 h of incubation. Again, among those fragments that did yield an outgrowth there was only a scant accumulation of cells.
To determine if the fusion toxin was interacting with cells still within the body ofthe plaque explant, versus cells that had recently migrated out of the tissue (and consequently been exposed to a higher concentration offusion toxin), explants were incubated free floating in serum-supplemented culture medium in the presence or absence of 10-8 M DAB389EGF, and proliferation was measured based on the incorporation of radiolabeled thymidine. Under these conditions the atherosclerotic tissue explants received a growth stimulus, but outgrowth of smooth muscle cells would not occur. 6% of cells in control tissue were labeled, as assessed by autoradiography; in contrast, no cells in lesions exposed to the fusion toxin were labeled. Thus, incubation with DAB389EGF prevented cell proliferation within the human atherosclerotic tissue. Discussion EGF receptor-targeted fusion proteins have attracted interest as a potential therapy for solid tumors (20) (21) (22) . DAB389EGF in particular has been shown to kill tumor cells in culture at very low concentrations and with rapid kinetics ( 12) . Furthermore, studies with animal tumor models have indicated that DAB389EGF can have a therapeutic effect at nontoxic doses (Shaw, J. P., manuscript in preparation). Targeted cytotoxic therapy may also be ofvalue in certain vascular disorders, characterized by the rapid accumulation of cells. Restenosis after angioplasty may be particularly amenable to cytotoxic therapy since the location of disease is predictable (i.e., the site of a previous catheter-based intervention) and the cytotoxic agent could be delivered to a localized, isolated region of the vessel (23, 24) thereby minimizing damage to normal tissues.
Our results demonstrate that DAB389EGF is highly cytotoxic to human vascular smooth muscle cells proliferating in culture. The fusion protein can prevent the outgrowth of smooth muscle cells from human atherosclerotic plaque explanted into a growth-promoting environment and can prevent proliferation within the plaque itself. We have shown that the effect is mediated specifically by the EGF receptor. It has been previously demonstrated that the intracellular events leading to cell death are identical to those associated with native diphtheria toxin (12) . Specifically, receptor-mediated endocytosis leads to the appearance of the molecule within endosomes. This is followed by translocation of fragment A of diphtheria toxin into the cytosol, where it catalyzes the covalent linkage of ADP-ribose to elongation factor-2. This reaction arrests protein synthesis.
Assessing the outgrowth of smooth muscle cells from ex- 
